Metformin 500 mg is primarily used to treat type 2 diabetes. It’s the most commonly prescribed first-line medication for managing blood sugar, approved for adults and children aged 10 and older. The 500 mg tablet is the standard starting dose, typically taken twice daily with meals, and gradually increased based on how well your blood sugar responds.
Why 500 mg Is the Starting Point
The 500 mg dose is where most people begin because it gives your body time to adjust. At this level, the medication is unlikely to produce a meaningful drop in blood sugar on its own. Clinically significant effects generally don’t appear until the daily dose reaches at least 1,500 mg. That’s why your prescriber will typically increase the dose in 500 mg increments each week until your blood sugar reaches target levels, up to a maximum of 2,550 mg per day for adults or 2,000 mg per day for children.
The gradual ramp-up isn’t about the drug being dangerous at higher doses. It’s about minimizing stomach problems. Jumping straight to a full dose is a common reason people abandon the medication early.
How Metformin Lowers Blood Sugar
Metformin works differently from most diabetes medications. Rather than pushing your pancreas to produce more insulin, it targets two key problems: how much sugar your liver releases into your bloodstream and how efficiently your intestines handle glucose.
Your liver constantly produces glucose, even between meals. In type 2 diabetes, that process goes into overdrive, flooding your blood with sugar you don’t need. Metformin acts primarily in the gut, where it increases glucose uptake through the intestinal wall and produces byproducts (mainly lactate and acetate) that travel through the portal vein to the liver. These byproducts change the chemical environment in the liver, essentially telling it to slow down glucose production. This gut-liver communication loop is the core of how the drug works.
Because metformin doesn’t force extra insulin production, it carries a very low risk of causing dangerously low blood sugar on its own. That safety profile is a big reason it’s remained the go-to starting medication for type 2 diabetes for decades.
Effects on Body Weight
Unlike many diabetes medications that cause weight gain, metformin is associated with modest weight loss. In clinical trials, the long-term average is about a 2% reduction in body weight. In real-world clinical practice, the effect tends to be larger, with patients losing around 7% of their starting weight on average.
A retrospective study found that people without diabetes lost a similar amount of weight as those with type 2 diabetes or prediabetes. At six months, both groups averaged about 6.5% weight loss. At 12 months, both groups averaged roughly 7.3 to 7.4% weight loss. While metformin is not FDA-approved as a weight loss drug, this effect is well documented and sometimes factors into prescribing decisions.
Digestive Side Effects and How to Manage Them
Stomach and intestinal problems are the most common complaint, affecting up to 20% of people who take metformin. The usual issues are diarrhea, nausea, and vomiting. For most people, these symptoms are worst during the first few weeks and tend to improve as the body adjusts, though the exact timeline varies from person to person.
Taking your dose with food makes a real difference. The standard recommendation is to take the 500 mg tablet with your morning and evening meals. Starting at a low dose and increasing gradually also helps your gut acclimate. If side effects persist, an extended-release (XR) version of metformin is available. It releases the drug more slowly, producing a lower peak concentration in your system. Interestingly, when researchers pooled data from multiple trials comparing the two formulations, the extended-release version didn’t show a statistically significant advantage for reducing gut symptoms. Still, many individuals do report better tolerance with it, and it’s a reasonable option if the standard tablet causes ongoing discomfort.
Vitamin B12 and Long-Term Use
One underappreciated risk of staying on metformin for years is vitamin B12 deficiency. Studies estimate that 10 to 30% of long-term users develop low B12 levels, with some research placing the number as high as 35%. The risk increases with higher doses and longer duration of use.
B12 deficiency can cause fatigue, numbness or tingling in the hands and feet, and difficulty with balance or memory. These symptoms overlap with diabetic nerve damage, so they’re easy to miss or misattribute. If you’ve been on metformin for several years, periodic B12 blood testing is worth discussing with your prescriber.
Who Should Not Take Metformin
Kidney function is the main factor that determines whether metformin is safe for you. Your kidneys clear the drug from your body, so reduced kidney function can cause it to accumulate to harmful levels. The key measurement is your estimated glomerular filtration rate (eGFR), a standard part of routine blood work.
- eGFR above 45: Metformin can generally be used without dose adjustment.
- eGFR between 30 and 45: Not recommended for new prescriptions. If you’re already taking it, your prescriber may reduce the dose and monitor kidney function more frequently.
- eGFR below 30: Metformin is contraindicated and should not be used.
People scheduled for imaging procedures involving contrast dye may need to temporarily stop metformin, since the dye can stress the kidneys. Heavy alcohol use also increases the risk of a rare but serious complication called lactic acidosis, where acid builds up in the blood faster than the body can clear it.
Off-Label Uses
While type 2 diabetes is the only FDA-approved indication, metformin is widely prescribed off-label for several related conditions. Polycystic ovary syndrome (PCOS) is one of the most common, where the drug helps by improving insulin resistance, which plays a central role in the hormonal imbalances driving the condition. It’s also frequently used for prediabetes prevention. The landmark Diabetes Prevention Program trial showed that metformin reduced the progression from prediabetes to diabetes by 31% over roughly three years, though lifestyle changes (diet and exercise) were even more effective at 58%.
Some clinicians prescribe metformin for insulin resistance that hasn’t yet reached the threshold of a prediabetes diagnosis, and there’s growing interest in its potential effects on aging and cancer risk. These uses remain investigational, without the same level of evidence backing the diabetes indication.